In March 2025, SFA Therapeutics announced that two head-to-head preclinical studies of its oral psoriasis therapy candidate, ...

Codex Labs has announced the launch of the first product in a new collection, KĀNGFÙ, that is focused on healing damaged skin ...

United States: Projected CAGR of 5.1%, with market value rising from USD 127.3 billion in 2025 to USD 209.4 billion by 2035, ...

The FDA has expanded the approval of Tremfya to include pediatric patients 6 years and older weighing at least 40kg for the treatment of moderate to severe plaque PsO and active PsA.

Meditation, biofeedback, aromatherapy, and other such therapies can relieve stress caused by psoriasis and fend off stress-triggered flares.

The U.S. Food and Drug Administration has approved Johnson & Johnson's Tremfya (guselkumab) for the treatment of plaque ...

The vibroacoustic sensor, which measures material changes in each layer of skin using small vibrations on the surface, has received £275,000 from Scottish Enterprise and just over £200,000 from the ...

Star Therapeutics has raised $125 million in new venture funding that will help propel its experimental blood disease drug through late-stage testing. Initially formed as a “hub-and-spoke” biotech ...

Tremfya is the first IL-23 inhibitor approved for pediatric plaque psoriasis and psoriatic arthritis, based on the PROTOSTAR trial's positive results. The PROTOSTAR trial demonstrated significant skin ...

In the Mediterranean diet group, 47.4% achieved a 75% reduction in PASI compared with 0% in the control group. HealthDay News — A 16-week Mediterranean diet intervention significantly improves ...

Psoriasis may not have a cure, but new research has found that significant relief could be achieved at the dinner table. In a clinical trial, scientists found that a Mediterranean diet could ...